Pharmacist-led structured care for patients with diabetic nephropathy

British Journal of Diabetes and Vascular Disease

Volumn 8, Issue 2, 2008, Pages 86-88

  Kelly, Christopher J G ^a   Booth, Gillian ^a  

^a Stirling Royal Infirmary   (United Kingdom)

Author keywords

Diabetes nephropathy; Healthcare delivery; Pharmacist; Structured care

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; CHOLESTEROL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; LOSARTAN; PERINDOPRIL; RAMIPRIL; SIMVASTATIN;

ADULT; AGED; ARTICLE; CLINICAL PROTOCOL; DIABETIC NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; FEMALE; HEALTH CARE DELIVERY; HUMAN; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; PATIENT CARE; PHARMACEUTICAL CARE; PHARMACIST; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE;

EID: 43449110107     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/14746514080080020601     Document Type: Article

References (11)

1. Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med 1999;341:1127-33.
2. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13.
3. Fried L, Orchard T, Kasiske B, for the Lipids and Renal Disease Progression Meta-analysis Study Group. Effect of lipid reduction on the progression of renal disease: A meta-analysis. Kidney International 2001;59:260-9.
4. Parving HH, Lehnert H, Brochner-Mortensen J et al. The Effect of Irbesartan on the Development of Diabetic Nephropathy in Patients with Type 2 Diabetes. N Engl J Med 2001;345:870-8.
5. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy. N Engl J Med 2001;345:861-9.
6. Gaede P, Vedel P, Larsen N, Jensen GVH, Parving HH, Pedersen O. Multifactorial Intervention and Cardiovascular Disease in Patients with Type 2 Diabetes. N Engl J Med 2003;348:383-93.
7. Joss N, Ferguson C, Brown C, Deighan CJ, Paterson KR, Boulton-Jones JM. Intensified treatment of patients with type 2 diabetes mellitus and overt nephropathy. QJM 2004;97:219-27.
8. Joss N, Paterson KR, Deighan CJ, Simpson K, Boulton-Jones JM. Diabetic nephropathy: how effective is treatment in clinical practice? QJM 2002;95:41-9.
9. Scottish Intercollegiate Guidelines Network (SIGN). Management of Diabetes 2001;20-23
10. Williams B, Poulter NR, Brown MJ et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 2004;328:634-40.
11. Leung WY, So WY, Tony PC et al. Effects of structured care by a pharmacist-diabetes specialist team in patients with Type 2 diabetic nephropathy. Am J Med 2005;118:1414.e21-1414.e27.